Top 10 Dry Eye Syndrome Companies in the World

The global dry eye syndrome market reached a value of US$ 4.8 Billion in 2023. As per the analysis by IMARC Group, the top companies in the dry eye syndrome industry are focusing on the development of novel drug delivery systems, such as punctal plugs and liposomal formulations, which improves the treatment's efficacy, eliminates the need for frequent application, and offers long-term relief, which is propelling the market growth. Furthermore, the rising geriatric population, which is more susceptible to dry eye syndrome due to decreased tear production, changes in tear compositions, and side effects of other medications, is providing an impetus to the market growth. Apart from this, the introduction of advanced diagnostics, such as imaging technologies and biomarker-based tests that provide more accurate results, allow early intervention, and prevent future complications, is positively influencing the market growth.

In line with this, the key players are focusing on the integration of various cutting-edge technologies, such as genomics, gene editing, and artificial intelligence (AI), which in turn is creating a positive outlook for the market. Moreover, the widespread prevalence of dry eye syndrome owing to the increasing utilization of electronic devices such as smartphones, tablets, and computers, which leads to extended screen time, is favoring the market growth. Along with this, the rising air pollution and associated factors, such as dust and smoke, which adversely affect eyes and exacerbate symptoms of dry eyes, are acting as another growth-inducing factor. Apart from this, the aggressive marketing and advertising activities by manufacturers through social media, print ads, and television (TV) commercials are supporting the market growth. Other factors, including increasing investment in the development of novel therapeutics, the rapid expansion of the healthcare industry, the rising prevalence of diabetes, and the growing adoption of contact lenses, are anticipated to drive the market growth. Looking forward, IMARC Group expects the market value to reach US$ 7.5 Billion by 2032, growing at a CAGR of 5% during the forecast period (2024-2032).

Learn about opportunities, challenges, and trends in the global dry eye syndrome market with IMARC’s market research report. Try a free sample today!

List of Top Companies Operating in the Dry Eye Syndrome Industry:

The global dry eye syndrome market has several major players including Akorn Operating Company LLC, Alimera Science, Allergan plc., Auven Therapeutics, Bausch + Lomb Incorporated, GlaxoSmithKline plc, Nicox S.A., Novartis AG, Otsuka Holdings Co. Ltd., and Santen Pharmaceutical Co. Ltd. More information about these companies has been provided below. 

1. Akorn Operating Company LLC

Akorn Operating Company LLC is a pharmaceutical enterprise that manufactures generic and branded prescription medications and ophthalmic products. Some of its offerings include inhalations, injections, nasal sprays, oral liquids and solids, and topical creams. The company’s products are extensively used in various therapeutic applications, such as pain management, dermatology, anesthesia, respiratory, ophthalmology, and cardiovascular diseases. Furthermore, Akorn Operating Company LLC is focused on expanding its product portfolio to meet rising consumer demands and strengthen its market presence.

2. Alimera Science

Alimera Science is a biopharmaceutical company specializing in the research, development, and commercialization of prescription ophthalmic medications. Its products are widely used to treat diabetic macular edema (DME), uveitis, retinal vein occlusion, and other retinal disorders. The company invests heavily in research to identify new drug candidates, optimize their formulations, and conduct clinical trials to evaluate their safety and efficacy. Alimera Science has also established a strong network of partnerships with distributors and healthcare providers.

3. Allergan plc.

Allergan plc. is a multinational company that produces pharmaceutical, biologic, and medical device products. It was recently acquired by AbbVie Inc., which is another research-based biopharmaceutical company. Allergan plc. is widely known for its Botox products, which are used to treat various conditions, including wrinkles, migraines, and muscle spasms. Furthermore, the company is also investing in advanced technologies, such as gene editing, artificial intelligence (AI), and machine learning (ML), to improve its product lineup and develop new treatments.

4. Auven Therapeutics

Auven Therapeutics is a private equity firm focused on acquiring controlling ownership in promising therapeutic products or platforms. It has built a diversified portfolio of biologics and small molecules for treating cancer, ophthalmic conditions, women’s health, and orphan diseases. Auven Therapeutics is also developing innovative therapies for various other diseases, such as ophthalmic conditions, including dry eye syndrome and glaucoma, as well as rare genetic diseases and neurodegenerative disorders.

5. Bausch + Lomb Incorporated

Bausch + Lomb Incorporated is a global eye health company that offers a wide range of products, including contact lenses, lens care products, pharmaceuticals, and surgical instruments. The company’s products are widely used to treat various eye conditions, such as glaucoma, dry eye, and infections. Moreover, it has developed a digital platform to provide multiple tools and services to consumers, such as online shopping, lens power calculator, and lens finder. Apart from this, the company also produces various eye and ear care products for dogs, such as wipes, washes, and supplements.

6. GlaxoSmithKline plc

GlaxoSmithKline plc is a global pharmaceutical manufacturer that produces generic drugs, specialty medicines, and consumer healthcare products. The company is widely known for its effective vaccines, which are used to treat various infectious diseases, such as human papillomavirus (HPV), meningitis, and pneumonia. Furthermore, GlaxoSmithKline plc is significantly investing in advanced technologies, such as functional genomics and artificial intelligence (AI), to find new treatments and gain advantages over competitors. Apart from this, the company is also focusing on developing wearable technologies that allow patients to track their symptoms and medication usage.

7. Nicox S.A.

Nicox S.A. is a French ophthalmic company that focuses on developing innovative solutions for eye diseases. Its product offerings include prescription and over-the-counter (OTC) medications and diagnostic tests for open-angle glaucoma, ocular hypertension, allergic conjunctivitis, and dry eyes. The company is leveraging various marketing strategies, such as digital advertising, social media campaigns, and physician education programs to build brand recognition and increase product awareness. Furthermore, it is focused on developing new drug delivery technologies and novel mechanisms of action in ophthalmology to expand its portfolio and increase sales.

8. Novartis AG

Novartis AG is a multinational pharmaceutical enterprise specializing in manufacturing healthcare products and medical devices. Its prescription drugs and medications cover a wide range of areas, including oncology, immunology, dermatology, respiratory, neuroscience, cardiovascular, and infectious diseases. The company has also formed several partnerships and collaborations with other companies and organizations to enhance its product portfolio and expand its market reach. Moreover, it is investing in digital health technologies, such as remote monitoring devices and mobile apps, to improve patient outcomes and streamline healthcare delivery.

9. Otsuka Holdings Co. Ltd.

Otsuka Holdings Co. Ltd. is a Japanese multinational company (MNC) that produces healthcare and pharmaceutical products. Along with this, it also offers various healthcare services, including diagnostic testing, medical information, and clinical research support. The company is also firmly committed to research and development (R&D) activities to create innovative solutions, improve patient outcomes, and increase profit. Moreover, it is acquiring various companies that share its core competencies to strengthen its market presence and improve profits.

10. Santen Pharmaceutical Co. Ltd.

Santen Pharmaceutical Co. Ltd. is a global organization specializing in ophthalmology. Its major products include anti-inflammatory drugs, anti-allergy drugs, anti-infective drugs, and intraocular lenses. Some of its recent innovations include a new eye drop formulation for dry eye syndrome and a new intraocular lens for cataract surgery. Furthermore, the company is expanding its global footprint by entering new markets and partnering with local players. It also focuses on patient-centric care to differentiate itself from competitors and improve patient outcomes.

About Author: